BCL2 and acute lymphoblastic leukemia: IS21 has been shown to reduce viability in four human T-ALL cell lines with a different Notch genetic background, TALL1, Loucy, and Molt3, which are characterized by high levels of the Bcl-2 protein, while being less effective on the GSI-resistant Jurkat cell line, with low Bcl-2 levels [119].